Hypoglycemia in Children and Young Adults with Cystic Fibrosis During Oral Glucose Tolerance Testing Vs. Continuous Glucose Monitoring

Overview

Journal Pediatr Pulmonol

Specialties Pediatrics
Pulmonary Medicine

Date 2023 Jun 23

PMID 37350354

Authors

Erin Finn

Cameron Severn

Laura Pyle

Justin Garrish

Timothy Vigers

Cecilia G Diniz Behn

Philip S Zeitler

Scott D Sagel

Kristen J Nadeau

Christine L Chan

Affiliations

Soon will be listed here.

Abstract

Background: Hypoglycemia is common in people with cystic fibrosis (pwCF) during oral glucose tolerance tests (OGTTs) and in the free-living setting, yet its pathophysiology remains unclear.

Objective: To evaluate hypoglycemia in children and young adults with CF by OGTT and continuous glucose monitoring (CGM).

Methods: A 3-h OGTT was performed in children and young adults with CF and healthy controls (HC). Individuals were classified as experiencing hypoglycemia on OGTT (glucose <70 mg/dL) or not. Insulin, C-peptide, glucose, glucagon, and incretins were measured. CGM was performed for 7 days in the free-living setting. Measures of insulin sensitivity, beta cell function accounting for insulin sensitivity, and insulin clearance were calculated.

Results: A total of 57 participants (40 CF and 17 HC) underwent assessment. Rates of hypoglycemia by OGTT were similar in pwCF (53%, 21/40) compared to HC (35%, 6/17), p = 0.23. PwCF compared to HC had higher A1c; on OGTT higher and later glucose peaks, later insulin peaks; and on CGM more glucose variability. CF Hypo+ versus CF Hypo- had higher lung function, higher insulin sensitivity, higher beta cell function accounting for insulin sensitivity, and decreased CGM variability. When comparing CF Hypo+ to HC Hypo+, although rates of hypoglycemia are similar, pwCF had blunted glucagon responses to hypoglycemia. OGTT hypoglycemia was not associated with CGM hypoglycemia in any group.

Conclusion: Youth with CF have increased insulin sensitivity and impaired glucagon response to hypoglycemia on OGTT. Hypoglycemia on OGTT did not associate with free-living hypoglycemia.

References

Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W . Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009; 32(9):1626-31. PMC: 2732133. DOI: 10.2337/dc09-0586. View

Aitken M, Szkudlinska M, Boyko E, Ng D, Utzschneider K, Kahn S . Impaired counterregulatory responses to hypoglycaemia following oral glucose in adults with cystic fibrosis. Diabetologia. 2020; 63(5):1055-1065. PMC: 7150633. DOI: 10.1007/s00125-020-05096-6. View

Pisprasert V, Ingram K, Lopez-Davila M, Munoz A, Garvey W . Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care. 2012; 36(4):845-53. PMC: 3609485. DOI: 10.2337/dc12-0840. View

Korten I, Kieninger E, Krueger L, Bullo M, Fluck C, Latzin P . Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study. Front Pediatr. 2022; 10:852551. PMC: 9070552. DOI: 10.3389/fped.2022.852551. View

Kelly A, De Leon D, Sheikh S, Camburn D, Kubrak C, Peleckis A . Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy. Am J Respir Crit Care Med. 2018; 199(3):342-351. PMC: 6835076. DOI: 10.1164/rccm.201806-1018OC. View

Armaghanian N, Markovic T, Brand-Miller J, Bye P, Moriarty C, Steinbeck K . Hypoglycaemia in cystic fibrosis: An analysis of a single centre adult cystic fibrosis clinic. J Cyst Fibros. 2017; 17(4):542-547. DOI: 10.1016/j.jcf.2017.11.015. View

Haliloglu B, Gokdemir Y, Atay Z, Abali S, Guran T, Karakoc F . Hypoglycemia is common in children with cystic fibrosis and seen predominantly in females. Pediatr Diabetes. 2016; 18(7):607-613. DOI: 10.1111/pedi.12470. View

Abdul-Ghani M, Abdul-Ghani T, Ali N, DeFronzo R . One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care. 2008; 31(8):1650-5. PMC: 2494641. DOI: 10.2337/dc08-0225. View

Ross S, Morrison D, McArthur R . Hypersecretion of gastric inhibitory polypeptide in nondiabetic children with cystic fibrosis. Pediatrics. 1981; 67(2):252-4. View

10.

Nyirjesy S, Sheikh S, Hadjiliadis D, De Leon D, Peleckis A, Eiel J . β-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose ≥155 mg/dL. Pediatr Diabetes. 2018; 19(7):1173-1182. PMC: 6364976. DOI: 10.1111/pedi.12700. View

11.

Cobelli C, Dalla Man C, Toffolo G, Basu R, Vella A, Rizza R . The oral minimal model method. Diabetes. 2014; 63(4):1203-13. PMC: 4179313. DOI: 10.2337/db13-1198. View

12.

Battezzati A, Battezzati P, Costantini D, Seia M, Zazzeron L, Russo M . Spontaneous hypoglycemia in patients with cystic fibrosis. Eur J Endocrinol. 2007; 156(3):369-76. DOI: 10.1530/eje.1.02344. View

13.

Granados A, Chan C, Ode K, Moheet A, Moran A, Holl R . Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis. J Cyst Fibros. 2019; 18 Suppl 2:S3-S9. DOI: 10.1016/j.jcf.2019.08.016. View

14.

Dalla Man C, Caumo A, Cobelli C . The oral glucose minimal model: estimation of insulin sensitivity from a meal test. IEEE Trans Biomed Eng. 2002; 49(5):419-29. DOI: 10.1109/10.995680. View

15.

. Nadirs of oral glucose tolerance tests are independent of age and sex. Diabetes Care. 1983; 6(4):405-8. DOI: 10.2337/diacare.6.4.405. View

16.

Piccinini F, Bergman R . The Measurement of Insulin Clearance. Diabetes Care. 2020; 43(9):2296-2302. PMC: 7440908. DOI: 10.2337/dc20-0750. View

17.

Chan C, Hope E, Thurston J, Vigers T, Pyle L, Zeitler P . Hemoglobin A Accurately Predicts Continuous Glucose Monitoring-Derived Average Glucose in Youth and Young Adults With Cystic Fibrosis. Diabetes Care. 2018; 41(7):1406-1413. PMC: 6014540. DOI: 10.2337/dc17-2419. View

18.

Frost F, Jones G, Dyce P, Jackson V, Nazareth D, Walshaw M . Loss of incretin effect contributes to postprandial hyperglycaemia in cystic fibrosis-related diabetes. Diabet Med. 2019; 36(11):1367-1374. DOI: 10.1111/dme.14121. View

19.

Gaines H, Jones K, Lim J, Medhi N, Chen S, Scofield R . Effect of CFTR modulator therapy on cystic fibrosis-related diabetes. J Diabetes Complications. 2021; 35(6):107845. PMC: 8113061. DOI: 10.1016/j.jdiacomp.2020.107845. View

20.

Radike K, Molz K, Holl R, Poeter B, Hebestreit H, Ballmann M . Prognostic relevance of hypoglycemia following an oral glucose challenge for cystic fibrosis-related diabetes. Diabetes Care. 2011; 34(4):e43. PMC: 3064065. DOI: 10.2337/dc10-2286. View